Reported 2 months ago
Amgen's second quarter earnings revealed a revenue of $8.4 billion, surpassing estimates of $8.34 billion, but slightly missing adjusted earnings expectations with $4.97 per share compared to the anticipated $4.98. The company's obesity drug, MariTide, holds potential for future earnings growth if it receives approval.
Source: YAHOO